氨基糖苷类药物市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球氨基糖苷类药物市值为 19 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 4%。它们广泛应用于治疗泌尿道感染、肺炎和败血症等疾病，凸显了它们在现代医疗保健中的重要作用。这些抗生素是抵抗细菌感染的基石，特别是在其他治疗方法可能失败的情况下。它们的多功能性以及抗菌素抗药性的日益普遍进一步巩固了它们在全球市场的需求。

世界各国政府将这些基本抗生素纳入补贴医疗保健系统和国家计划，为氨基糖苷类药物市场的成长做出了重大贡献。这不仅提高了可近性，而且确保了它们可用于管理各种传染病。此外，静脉给药吸入溶液等先进剂型的开发和采用扩大了其在治疗支气管疾病中的应用，从而增加了对氨基糖苷类药物的需求。

市场依产品细分为新霉素、妥布霉素、庆大霉素、阿米卡星、巴龙霉素、链霉素及其他产品。 2024 年，庆大霉素成为领先市场，市场估值达 5.416 亿美元。抗药性细菌感染的日益普及增加了人们对庆大霉素等强效抗生素的依赖。随着抗菌素抗药性持续挑战全球医疗保健格局，庆大霉素的功效使其成为医疗保健专业人士的首选。

从应用角度来看，氨基糖苷类药物市场分为细菌感染、结核病和其他用途。细菌感染占据市场主导地位，2024 年占 65.5% 的份额。院内感染，例如肺炎、泌尿道感染和血流感染仍然是令人担忧的问题，特别是由革兰氏阴性病原体如铜绿假单胞菌和肺炎克雷伯菌引起的感染。这些持续存在的挑战推动了对氨基糖苷类药物作为可靠治疗药物的需求。

受细菌感染高发性和先进的医疗保健基础设施的推动，美国氨基糖苷类药物市场价值在 2024 年将达到 7.267 亿美元。诊断能力的提升使得有针对性的治疗策略成为可能，促进了氨基糖苷类药物的精准有效使用。随着细菌感染的盛行率持续上升，预计这些因素将在未来几年维持该地区市场的成长势头。

目录

第 1 章：方法论与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 细菌感染发生率上升
    • 增加外科手术
    • 提高对抗菌素抗药性的认识
    • 联合治疗的技术进步
  • 产业陷阱与挑战
    • 替代疗法的可用性
    • 严格的监管要求
• 成长潜力分析
• 监管格局
• 管道分析
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第 5 章：市场估计与预测：按产品，2021 年至 2034 年

• 主要趋势
• 新霉素
• 妥布霉素
• 庆大霉素
• 阿米卡星
• 巴龙霉素
• 链霉素
• 其他产品

第 6 章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 细菌感染
  • 呼吸道感染
  • 皮肤和软组织感染
  • 骨感染
  • 泌尿道感染 (UTI)
• 结核
• 其他应用

第 7 章：市场估计与预测：按管理路线，2021 年至 2034 年

• 主要趋势
• 注射剂
• 口服
• 主题
• 眼科

第 8 章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 医院和诊所
• 研究和学术机构
• 家庭护理设置
• 其他最终用户

第 9 章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Aurobindo Pharma
• Bausch Health Companies
• Cipla
• Fresenius Kabi
• Kremoint Pharma (Bliss GVS Pharma)
• Meiji Seika Pharma (Meiji Holdings)
• Novartis
• Perrigo Company
• Pfizer
• Sun Pharmaceutical Industries
• Sanofi
• Teva Pharmaceuticals

The Global Aminoglycosides Market was valued at USD 1.9 billion in 2024 and is poised to grow at a CAGR of 4% from 2025 to 2034. Aminoglycosides are renowned for their robust efficacy against Gram-negative bacteria, making them indispensable in the treatment of various infectious diseases. Their widespread use in addressing conditions such as urinary tract infections, pneumonia, and sepsis underscores their vital role in modern healthcare. These antibiotics are a cornerstone in combating bacterial infections, particularly in scenarios where other treatments may falter. Their versatility, in line with the rising prevalence of antimicrobial resistance, has further cemented their demand in global markets.

Governments worldwide contribute significantly to the growth of the aminoglycosides market by incorporating these essential antibiotics into subsidized healthcare systems and national programs. This not only boosts accessibility but also ensures their availability for managing a broad spectrum of infectious diseases. In addition, the development and adoption of advanced formulations, such as inhalation solutions for intravenous administration, have expanded their application in treating bronchial diseases, amplifying the demand for aminoglycosides.

The market is segmented by product into neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, and other products. In 2024, gentamicin emerged as the leading segment with a market valuation of USD 541.6 million. The increasing prevalence of drug-resistant bacterial infections has heightened the reliance on potent antibiotics like gentamicin. As antimicrobial resistance continues to challenge the global healthcare landscape, gentamicin's efficacy has made it a preferred choice among healthcare professionals.

From an application standpoint, the aminoglycosides market is categorized into bacterial infections, tuberculosis, and other uses. Bacterial infections dominated the market, accounting for a 65.5% share in 2024. This category encompasses respiratory infections, skin and soft tissue infections, bone infections, and urinary tract infections. Hospital-acquired infections, such as pneumonia, urinary tract infections, and bloodstream infections, remain significant concerns, particularly those caused by Gram-negative pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae. These persistent challenges drive the demand for aminoglycosides as reliable therapeutic agents.

The United States aminoglycosides market was valued at USD 726.7 million in 2024, driven by a high incidence of bacterial infections and advanced healthcare infrastructure. Improved diagnostic capabilities have enabled targeted treatment strategies, fostering the precise and effective use of aminoglycosides. As bacterial infections continue to rise in prevalence, these factors are expected to sustain market growth momentum in the region over the coming years.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of bacterial infection
    • 3.2.1.2 Increasing surgical procedures
    • 3.2.1.3 Increasing awareness of antimicrobial resistance
    • 3.2.1.4 Technological advancement in combination therapies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Availability of alternative therapies
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Neomycin
• 5.3 Tobramycin
• 5.4 Gentamicin
• 5.5 Amikacin
• 5.6 Paromomycin
• 5.7 Streptomycin
• 5.8 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Bacterial infection
  • 6.2.1 Respiratory infections
  • 6.2.2 Skin and soft tissue infections
  • 6.2.3 Bone infections
  • 6.2.4 Urinary Tract Infections (UTIs)
• 6.3 Tuberculosis
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Injectable
• 7.3 Oral
• 7.4 Topical
• 7.5 Ophthalmic

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Research and academic institutes
• 8.4 Homecare settings
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Aurobindo Pharma
• 10.2 Bausch Health Companies
• 10.3 Cipla
• 10.4 Fresenius Kabi
• 10.5 Kremoint Pharma (Bliss GVS Pharma)
• 10.6 Meiji Seika Pharma (Meiji Holdings)
• 10.7 Novartis
• 10.8 Perrigo Company
• 10.9 Pfizer
• 10.10 Sun Pharmaceutical Industries
• 10.11 Sanofi
• 10.12 Teva Pharmaceuticals